By Himangshu Ranjan Bhuyan
Healthcare is an indispensable element of human life, essential not only for individual physical and mental well-being but also for the overall progress of society, economic stability, and the foundation of social justice. The quality, affordability, and equitable access to healthcare for all sections of society are considered benchmarks of a society’s development. However, in recent decades, the relentless and unpredictable rise in drug prices has plunged this critical sector into a profound crisis. The escalating cost of medicines has made healthcare expenses unbearable for the common person, resulting in increased health disparities across different sections of society.
Several complex and interconnected factors contribute to the rising cost of medicines. The primary and most significant factor is the exorbitant cost of research and development (R&D) for drugs. The entire process, from the discovery of a new drug to its availability in the market, is extremely time-consuming, complex, and costly. The research process involves initial testing, animal trials, and multiple phases of clinical trials on humans. The success rate of these trials is very low, with many promising drugs failing at the clinical trial stage. Out of thousands of potential compounds in the early stages of research, only a handful make it to the market. The cost of this process can sometimes exceed hundreds of crores of rupees, and pharmaceutical companies seek to ensure profits from their investments. Consequently, the burden of failed research costs is placed on successful drugs, and to recover these expenses, companies set extremely high prices for medicines. This trend is particularly evident in drugs developed for complex diseases such as cancer, hepatitis C, or rare genetic disorders. The annual treatment cost for some new cancer drugs can exceed several lakhs of rupees per patient, which is beyond the reach of the common person. As a result, many patients are deprived of access to treatment, severely impacting their quality of life.
Market dynamics play a significant role in the rising cost of medicines. The lack of competition in the pharmaceutical market allows some companies to establish monopolistic control. Especially in the case of drugs for rare diseases, where alternative treatments are scarce, companies can arbitrarily set prices. The patent system further strengthens this monopolistic dominance. Through patents, pharmaceutical companies gain exclusive rights to produce and sell their drugs for a specific period, preventing the production of generic medicines. Generic drugs are generally much cheaper than branded ones, but their production is not possible until the patent expires. As a result, patients are forced to rely on expensive branded drugs. For instance, some drugs used to treat diseases like hepatitis C were initially priced extremely high. Although the availability of generic versions later reduced prices to some extent, these drugs remain unaffordable for many patients. Additionally, some companies employ strategies to extend patent terms, such as applying for new patents through minor modifications to drugs, delaying the availability of generics. Such strategies keep drug prices high for longer periods, which is highly detrimental to patients.
The cost of drug production and the complexity of distribution also contribute significantly to price increases. The use of advanced technology, rising costs of raw materials, and compliance with regulatory standards in the production process increase manufacturing costs. For example, biotechnology-based drugs, such as monoclonal antibodies or those used in gene therapy, require highly complex production processes. The cost of these processes is significantly higher than that of conventional drugs, leading to higher prices. Additionally, intermediaries in the drug distribution system, such as wholesalers, retailers, and pharmacies, add their profit margins, further increasing the final price of medicines. In some cases, a significant portion of a drug’s price goes to these intermediaries, placing an additional financial burden on patients. In rural areas, the cost of drug distribution increases, making medicines more expensive compared to urban areas, where the same drugs may be relatively cheaper.
Some countries have strict policies to regulate drug prices, ensuring affordability for the general population. For example, in certain European Union countries, government regulations control drug prices, and health insurance systems reduce patient costs. However, in countries like India, where the prices of some drugs are regulated under the National List of Essential Medicines (NLEM), many life-saving drugs remain outside this list. As a result, companies have almost complete freedom in pricing these drugs, leading to price disparities. Furthermore, the lack of vigilance by regulatory authorities allows some companies to exploit loopholes in existing policies, resulting in excessive price hikes. Some companies have suddenly increased the prices of life-saving drugs, causing widespread discontent among patients. The absence of government intervention in such situations further complicates the issue.
The impact of rising drug prices varies across different sections of society. For low and middle-income groups, this price hike directly affects the affordability of healthcare. For many families, bearing the cost of medicines becomes impossible, forcing them to either abandon treatment or fall into debt. This problem is even more severe in rural areas, where access to healthcare is already limited, and rising drug prices exacerbate this disparity. For example, chronic diseases such as diabetes, hypertension, or heart disease require regular medication. The rising cost of these medicines places immense financial strain on patients. In some cases, patients reduce their dosage or stop treatment altogether, leading to a deterioration in their health. In the case of diabetic patients, the rising cost of insulin has caused many to skip regular medication, increasing the risk of complications such as kidney problems or heart disease.
Children, the elderly, and those with chronic illnesses are the most affected by this issue. In the case of children, particularly those with rare genetic disorders requiring expensive drugs, families face both economic and emotional strain. For example, drugs used to treat conditions like Spinal Muscular Atrophy (SMA) can cost crores of rupees, which is unaffordable for ordinary families. For the elderly, who often suffer from multiple ailments, the cost of medicines is disproportionately high compared to their limited income. As a result, many elderly individuals neglect their health, leading to a decline in their quality of life. Additionally, for those with chronic illnesses, the ongoing cost of regular medication becomes a persistent financial burden, reducing their families’ ability to meet other essential expenses, such as education or food.
The rising cost of medicines has widened health disparities in society. While the wealthy and elite can afford expensive drugs, it is nearly impossible for the poor and low-income groups. This has increased the gap in access to healthcare between the rich and the poor. This disparity not only affects individual quality of life but also has a negative impact on the social and economic stability of society as a whole. Lack of access to healthcare reduces workforce productivity, directly impacting the economy. For instance, the absence of treatment for chronic diseases reduces workers’ efficiency, adversely affecting companies and the national economy. Furthermore, rising drug prices impact mental health, as the financial burden of expensive treatments leads to increased stress, anxiety, and depression in families. In poor families, the need to cover drug costs often leads to selling assets, taking loans, or cutting back on other essential expenses, negatively affecting their overall quality of life.
Addressing this complex issue of rising drug prices requires robust measures. Stricter and more comprehensive policies are needed to regulate drug prices. Expanding the scope of the National List of Essential Medicines to include more life-saving drugs can make price regulation more effective and increase affordability for the common person. In India, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of some drugs, but the lack of regulation for many drugs outside this list increases the financial burden on patients. Additionally, simplifying the production and distribution of generic drugs can enhance the availability of affordable medicines. India has already made significant progress in generic drug production, but further improvements are needed in terms of quality, distribution efficiency, and availability in rural areas. Initiatives like Jan Aushadhi Kendras have been successful in providing affordable medicines, but increasing their number and scope can further enhance accessibility. Expanding the number of Jan Aushadhi Kendras and ensuring a wider range of medicines are available at these centers can make medicines more affordable for the general population.
To reduce the cost of drug research and development, public-private partnerships can be utilized. Collaboration between the government, research institutions, and pharmaceutical companies can lower the cost of developing new drugs. For example, direct government funding for research can help control drug prices. Additionally, simplifying the clinical trial process for new drugs can reduce costs, while ensuring no compromise on quality. The use of artificial intelligence (AI) and data analytics can accelerate the identification of promising compounds in the early stages of research, reducing R&D costs. Similarly, strengthening the health insurance system can alleviate the financial burden of drug costs. In countries like India, access to health insurance is still limited, and for many, insurance does not cover drug costs. A universal health insurance system could address this issue. Programs like Ayushman Bharat have improved access to healthcare, but expanding their scope to include greater coverage for drug costs can provide further relief. Additionally, private health insurance companies can be encouraged to introduce policies specifically covering drug costs, particularly for chronic diseases, to reduce patients’ financial burdens.
Raising awareness in the healthcare sector is crucial. Educating the public about drug prices, the benefits of generic medicines, and health insurance can empower them to make informed decisions. Promoting health education in rural areas can make people aware of proper drug use and affordable alternatives. Dispelling misconceptions about the quality of generic medicines can encourage their use. Furthermore, the lack of accurate information in the healthcare sector leads many people to incur unnecessary expenses. Many patients opt for branded drugs over generics, increasing their costs.
Reducing the role of intermediaries in the drug distribution system can help control prices. Establishing direct drug distribution systems through government initiatives can reduce intermediaries’ profit margins. Additionally, increasing the number of pharmacies and distributing medicines through health centers in rural areas can enhance affordability. For example, introducing mobile pharmacies in rural areas can improve drug availability.
International cooperation can also contribute to reducing drug prices. Collaboration with organizations like the World Health Organization (WHO) can lead to policies that enhance drug affordability. Establishing international funding for the production of drugs for rare diseases can lower their prices. Additionally, providing flexibility in intellectual property rights can facilitate the production of generic drugs. India has already played a leading role in generic drug production for many countries, and this experience can be leveraged internationally. India’s role in producing generic drugs for HIV/AIDS treatment has increased drug affordability in various countries.
Increasing transparency in drug pricing is essential. The lack of transparency in the pricing process allows companies to set excessive prices. Governments can enhance oversight of the pricing process and publish public information about it to ensure transparency. For example, disclosing clear information about production costs, research expenses, and profit margins can pressure companies to regulate prices.
Enhancing local drug production capacity is necessary. While India has made significant progress in drug manufacturing, it still relies on foreign sources for some complex drugs. Increasing local production capacity can reduce the cost of importing raw materials and make it easier to control drug prices. For instance, establishing local research and production centers for biotechnology-based drugs can lower their prices.
Addressing the issue of rising drug prices requires more than short-term measures; long-term and sustainable solutions are needed. Improving healthcare infrastructure can enhance both drug affordability and the quality of healthcare services. Increasing the number of health centers and hospitals in rural areas, ensuring the availability of doctors and healthcare workers, and strengthening drug distribution systems can lead to progress in addressing this issue. Additionally, increasing the use of technology in healthcare can reduce drug costs. Technologies like telemedicine can improve healthcare access in rural areas, potentially reducing the need for certain medications.
In conclusion, addressing the issue of rising drug prices requires the cooperation of all sections of society. Collaboration between the government, pharmaceutical companies, healthcare providers, and the public can lead to solutions. Healthcare is not just a privilege but an essential human right. Rising drug prices undermine this right, and addressing this issue requires collective action. By resolving this problem, we can not only improve individual quality of life but also strengthen the foundation of equality and justice in society. To tackle this challenge, we must all work together to ensure that healthcare remains a right for all, not just a privilege for the wealthy.
(The writer can be reached at himangshur1989@gmail.com)
